Clinical bottom line
Genomic advances have substantially enhanced the understanding of hereditary hearing loss (HHL), enabling more precise diagnosis and opening avenues for targeted therapies. Identification of causative gene mutations informs prognosis, guides genetic counseling, and increasingly supports translational approaches such as gene therapy, particularly in syndromic forms like Usher syndrome. Despite progress, heterogeneity in genetic etiologies and incomplete genotype-phenotype correlations present challenges. Integration of genomic testing into clinical practice is becoming essential for personalized management of HHL (Iuliano et al., 2024; Saenz-Roldan et al., 2024).
What the evidence shows
Iuliano et al. (2024) highlight recent genomic discoveries in inherited disorders, including hearing loss, emphasizing the role of next-generation sequencing in identifying pathogenic variants across numerous genes implicated in HHL. They underscore the clinical utility of comprehensive genetic panels for diagnosis.
Saenz-Roldan et al. (2024) review translational gene therapy efforts targeting hereditary hearing loss, focusing on preclinical models of Usher syndrome 1B and DFNB9. Their work demonstrates proof-of-concept for gene replacement strategies that restore auditory function, signaling potential future therapeutic options.
Owrang et al. provide mechanistic insights linking gene mutations to cochlear dysfunction, elucidating molecular pathways involved in hair cell development and maintenance. This mechanistic understanding supports targeted intervention development.
Allanson et al. (2004) and Reardon et al. (2004) describe syndromic forms of genetic hearing loss associated with systemic abnormalities, highlighting the importance of genetic diagnosis for comprehensive patient care.
Gorlin et al. (2004) offer a historical perspective on genetic hearing loss, contextualizing current genomic advances within decades of research.
Caveats and uncertainty
Genetic heterogeneity is vast, with over 100 genes implicated, complicating diagnostic interpretation.
Variants of uncertain significance remain common, limiting definitive diagnosis in some cases.
Phenotypic variability and incomplete penetrance challenge prediction of clinical outcomes based on genotype alone.
Gene therapy approaches are largely preclinical; clinical efficacy and safety data are awaited.
Access to comprehensive genomic testing and counseling may be limited in some settings.
How this may change practice
Routine incorporation of genomic testing in patients with unexplained hearing loss will improve diagnostic yield and enable personalized management.
Genetic counseling should be integrated early to inform families about inheritance patterns, prognosis, and reproductive options.
Emerging gene therapies may offer future disease-modifying treatments, particularly for syndromic and early-onset forms.
Multidisciplinary collaboration among otolaryngologists, geneticists, and audiologists will optimize care.
Clinicians should remain updated on evolving genomic technologies and therapeutic trials to guide patient discussions.